These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 17362994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network Group.
    J Neurol Sci; 2009 Nov 15; 286(1-2):109-13. PubMed ID: 19615696
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 15; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Long-term prevention of MS: effectiveness alone is not enough].
    Haas J.
    Krankenpfl J; 2005 Nov 15; 43(7-10):237. PubMed ID: 16515307
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D.
    Cardiovasc Ther; 2014 Apr 15; 32(2):33-9. PubMed ID: 24119301
    [Abstract] [Full Text] [Related]

  • 13. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
    Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M.
    Neurol Clin; 2011 May 15; 29(2):309-21. PubMed ID: 21439443
    [Abstract] [Full Text] [Related]

  • 14. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B.
    Mult Scler; 2008 Jun 15; 14(5):636-9. PubMed ID: 18566027
    [Abstract] [Full Text] [Related]

  • 15. Treatment of pediatric multiple sclerosis and variants.
    Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, Tenembaum S, International Pediatric MS Study Group.
    Neurology; 2007 Apr 17; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
    [Abstract] [Full Text] [Related]

  • 16. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N, Stepień A, Chalimoniuk M.
    Pol Merkur Lekarski; 2013 Mar 17; 34(201):135-9. PubMed ID: 23700821
    [Abstract] [Full Text] [Related]

  • 17. Therapy of MS.
    Vosoughi R, Freedman MS.
    Clin Neurol Neurosurg; 2010 Jun 17; 112(5):365-85. PubMed ID: 20362388
    [Abstract] [Full Text] [Related]

  • 18. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G.
    Clin Ther; 2009 Jun 17; 31(6):1142-57. PubMed ID: 19695384
    [Abstract] [Full Text] [Related]

  • 19. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2008 Jun 17; 60(6):279-84. PubMed ID: 18824855
    [Abstract] [Full Text] [Related]

  • 20. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR.
    Arch Neurol; 2008 Mar 17; 65(3):337-44. PubMed ID: 18195134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.